Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Lymphoma, non-Hodgkin lymphoma, child
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Results 1-25 of 117 for your search:
Start Over
Mature B-Cell Lymphoma And Leukemia Study III
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Status: Active
Age: 0 to 21
Sponsor: Other
Protocol IDs: SJBC3, NCT01046825
Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and under
Sponsor: NCI, Other
Protocol IDs: ANHL1131, NCI-2012-01963, CDR0000732604, IGR2009/1593, 2010-019224-31, U10CA098543, U10CA180886, COG-ANHL1131, NCT01595048
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: not specified
Sponsor: NCI, Other
Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, P30CA015704, NCT01231412
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
Phase: Phase III
Type: Treatment
Status: Active
Age: 65 and under
Sponsor: Pharmaceutical / Industry
Protocol IDs: CB-AB006, 2012-0166, NCT01854567
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 2 to 30
Sponsor: NCI
Protocol IDs: NCI-2014-00712, AALL1231, U10CA180886, U10CA098543, NCT02112916
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: 95-024, P30CA008748, MSKCC-95024, NCI-V95-0685, NCT00002663
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 65 and under
Sponsor: NCI, Other
Protocol IDs: 1409.00, NCI-2010-00130, P30CA015704, FHCRC-1409.00, 4903, NCI-G00-1776, NCT00005803
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 2230.00, NCI-2010-00106, P01CA078902, P30CA015704, FHCRC-2230.00, IR-6771, NCT00789776
Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 21
Sponsor: NCI, Other
Protocol IDs: ADVL0912, COG-ADVL0912, CDR0000647587, NCT00939770
Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 21
Sponsor: Other
Protocol IDs: T2008-002, NCT00981799
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 6 montha to 70
Sponsor: Other
Protocol IDs: J1055, NA_00039823, NCT01203722
Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Active
Age: 6 months to 85
Sponsor: Other
Protocol IDs: J1151, NA_00048378, NCT01342289
Phase I/II MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 13 to 60
Sponsor: NCI, Other
Protocol IDs: BMT236, SU-09142011-8407, NCT01660607
Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 12 to 65
Sponsor: Other
Protocol IDs: 2012-0506, NCI-2012-02055, NCT01701986
Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 30 and under
Sponsor: Other
Protocol IDs: NYMC 542, L 10, 819, NCT01842672
Safety and Tolerability of HSC835 in Patients Undergoing Single Umbilical Cord Blood Transplant
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specifiec
Sponsor: Pharmaceutical / Industry
Protocol IDs: CHSC835X2202, NCT01930162
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Other
Protocol IDs: 2013-0186, NCI-2014-01025, NCT01983969
Haplo-identical SCT for HR Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: SCT 0813 Haplo, NCT02053545
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Under 22
Sponsor: Other
Protocol IDs: AAAK8060, NCT02061800
Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 3 months to 21 years
Sponsor: Pharmaceutical / Industry
Protocol IDs: BP-004, NCT02065869
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 6 months to less than 18 years
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3475-051, 2014-002950-38, NCT02332668
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
Phase: Phase II
Type: Treatment
Status: Active
Age: 8 to 80
Sponsor: NHLBI
Protocol IDs: 990050, 99-H-0050, NHLBI-99-H-0050, NCT00003838
EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection
Phase: Phase II
Type: Treatment
Status: Active
Age: 4 and over
Sponsor: NCI
Protocol IDs: 010030, 01-C-0030, NCI-01-C-0030, NCI-2890, 2890, NCT00020384, NCT00006436
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
Phase: Phase II
Type: Treatment
Status: Active
Age: 45 and under
Sponsor: Other
Protocol IDs: 2005LS043, UMN-MT2005-10, UMN-0507M71475, UMN-2005LS043, UMN-BMT-MT2005-10, NCT00309842
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 70
Sponsor: Other
Protocol IDs: 2001LS058, UMN-MT2001-10, 0108M06725, UMN-2001LS058, NCT00303719
Start Over